Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Prövning mot obotlig typ 2-diabetes (CAPTAIN-T2D) (CAPTAIN-T2D)

5 oktober 2026 uppdaterad av: Sparrow Pharmaceuticals

Clofutriben och Placebo Fas 2-studie mot Intractable Typ 2-diabetes (CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.

The trial consists of two parts.

Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.

During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.

Studietyp

Interventionell

Inskrivning (Beräknad)

1500

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Chandler, Arizona, Förenta staterna, 85225
      • Tucson, Arizona, Förenta staterna, 85711
    • California
      • Fountain Valley, California, Förenta staterna, 92708
        • Rekrytering
        • Ark Clinical Research - Fountain Valley
        • Kontakt:
      • Huntington Park, California, Förenta staterna, 90255
      • La Mesa, California, Förenta staterna, 91942
      • Long Beach, California, Förenta staterna, 90815
      • Los Angeles, California, Förenta staterna, 90057
      • Los Angeles, California, Förenta staterna, 90015
        • Rekrytering
        • Los Angeles Institute for Metabolic Research
        • Kontakt:
      • Northridge, California, Förenta staterna, 98433
      • San Diego, California, Förenta staterna, 92120
    • Florida
      • Edgewater, Florida, Förenta staterna, 32132
      • Fort Lauderdale, Florida, Förenta staterna, 33312
        • Rekrytering
        • The Center for Diabetes and Endocrine Care
        • Kontakt:
      • Miami, Florida, Förenta staterna, 33173
      • New Port Richey, Florida, Förenta staterna, 34652
      • Port Charlotte, Florida, Förenta staterna, 33952
        • Rekrytering
        • Innovative Research Institute
        • Kontakt:
      • Port Orange, Florida, Förenta staterna, 32127
      • Winter Park, Florida, Förenta staterna, 32789
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30303
        • Rekrytering
        • Emory University School of Medicine
        • Kontakt:
      • Columbus, Georgia, Förenta staterna, 31904
    • Idaho
      • Boise, Idaho, Förenta staterna, 83709
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60607
        • Rekrytering
        • Chicago Clinical Research Institute
        • Kontakt:
          • Manognya Clinical Research Manager
          • Telefonnummer: 303 3127913241
          • E-post: manognya@ccrii.us
    • Iowa
      • West Des Moines, Iowa, Förenta staterna, 50226
        • Rekrytering
        • Iowa Diabetes and Endocrinology Research Center
        • Kontakt:
    • Kansas
      • Wichita, Kansas, Förenta staterna, 67226
        • Rekrytering
        • Alliance for Multispecialty Research - Wichita East
        • Kontakt:
    • Kentucky
      • Edgewood, Kentucky, Förenta staterna, 41017
    • Louisiana
      • Lafayette, Louisiana, Förenta staterna, 70508
      • Metairie, Louisiana, Förenta staterna, 70006
        • Rekrytering
        • NOLA Care Clinical Research
        • Kontakt:
      • New Orleans, Louisiana, Förenta staterna, 70112
        • Rekrytering
        • Tulane University School of Medicine
        • Kontakt:
    • Maryland
      • Rockville, Maryland, Förenta staterna, 20854
    • Massachusetts
      • Springfield, Massachusetts, Förenta staterna, 011030
    • Michigan
      • Troy, Michigan, Förenta staterna, 48085
        • Rekrytering
        • Oakland Medical Research Center
        • Kontakt:
    • Nebraska
      • Lincoln, Nebraska, Förenta staterna, 68510
      • Omaha, Nebraska, Förenta staterna, 68134
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89148
      • Las Vegas, Nevada, Förenta staterna, 89108
    • New York
      • Albany, New York, Förenta staterna, 12203
        • Rekrytering
        • Albany Medical College
        • Kontakt:
    • North Carolina
      • Chapel Hill, North Carolina, Förenta staterna, 27514
        • Rekrytering
        • University of North Carolina at Chapel Hill
        • Kontakt:
      • Greenville, North Carolina, Förenta staterna, 27834
      • Morehead City, North Carolina, Förenta staterna, 28557
      • Wilmington, North Carolina, Förenta staterna, 28401
        • Rekrytering
        • PMG Research of Wilmington, LLC
        • Kontakt:
    • Ohio
      • Cincinnati, Ohio, Förenta staterna, 45219
        • Rekrytering
        • Velocity Clinical Research, Cincinnati, Mt. Auburn
        • Kontakt:
      • Cincinnati, Ohio, Förenta staterna, 45242
        • Rekrytering
        • Velocity Clinical Research - Cincinnati, Blue Ash
        • Kontakt:
      • Columbus, Ohio, Förenta staterna, 43201
      • Columbus, Ohio, Förenta staterna, 43215
        • Rekrytering
        • Remington Davis, Inc
        • Kontakt:
    • Oregon
      • Eugene, Oregon, Förenta staterna, 97404
        • Rekrytering
        • Willamette Valley Clinical Studies
        • Kontakt:
    • Pennsylvania
      • West Chester, Pennsylvania, Förenta staterna, 19380
    • South Carolina
      • Anderson, South Carolina, Förenta staterna, 29621
      • Mt. Pleasant, South Carolina, Förenta staterna, 29464
    • Texas
      • Austin, Texas, Förenta staterna, 78759
      • Dallas, Texas, Förenta staterna, 75230
      • Houston, Texas, Förenta staterna, 77040
      • Lampasas, Texas, Förenta staterna, 76550
        • Rekrytering
        • Radiance Clinical Research
        • Kontakt:
      • Lewisville, Texas, Förenta staterna, 75057
      • Mission, Texas, Förenta staterna, 78572
        • Rekrytering
        • Texas Valley Clinical Research - Mission, TX
        • Kontakt:
      • Round Rock, Texas, Förenta staterna, 78681
        • Rekrytering
        • Texas Diabetes & Endocrinology, P.A. - Round Rock
        • Kontakt:
      • San Antonio, Texas, Förenta staterna, 78229
        • Rekrytering
        • Diabetes & Glandular Disease Clinic, P.A.
        • Kontakt:
      • San Antonio, Texas, Förenta staterna, 78251
        • Rekrytering
        • Texas Valley Clinical Research - San Antonio TX
        • Kontakt:
      • Seabrook, Texas, Förenta staterna, 77586
      • Weslaco, Texas, Förenta staterna, 78596
        • Rekrytering
        • Texas Valley Clinical Research, LLC
        • Kontakt:
    • Utah
      • West Jordan, Utah, Förenta staterna, 84088
        • Rekrytering
        • Velocity Clinical Research, Salt Lake City
        • Kontakt:
    • Virginia
      • Suffolk, Virginia, Förenta staterna, 23435
      • Vienna, Virginia, Förenta staterna, 22182

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • From Screening 1

    • Age at least 18 years.

    • HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).

    • Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).

    • Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.

    • Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.

    • At least one of the following

      • ≥3 stable and adequate ADMs;
      • diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
      • hypertension requiring ≥2 adequately dosed AHMs;
      • adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
      • adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
      • evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
      • or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.

At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.

At Screening 2

  • HbA1c ≥7.5% at Screening 2. At Day 1
  • No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.

Exclusion Criteria:

  • New-onset diabetes (onset <1 year in the past).

  • Unwillingness to maintain with current glucose-lowering regimen during the trial.

  • Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.

  • Unwillingness to comply with CGM or other trial procedures.

  • Investigator considers the patient will otherwise be unwilling or unable to complete the trial.

  • Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.

  • Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).

  • Any of the following in medical history:

    • Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
    • A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
    • Hypersensitivity or severe reaction to dexamethasone;
    • Pheochromocytoma, or suspicion thereof;
    • Anorexia, or other eating disorder;
    • Glucocorticoid resistance;
    • Multiple sclerosis;
    • Significant hepatic impairment (e.g., Child-Pugh Class B or C);
    • Idiopathic thrombocytopenic purpura;
    • Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
    • Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
    • Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
    • Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
    • Any of the following in medication history:
    • Any of the excluded medications listed in Section 6.9;
    • Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
    • Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
    • Pregnancy (including a positive urine test) or current breast feeding.

From Screening 2

• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:

  • wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
  • a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
  • supraclavicular/dorsocervical fat accumulation;
  • irounding of the face (especially compared with prior photos);
  • skin changes (violaceous striae, skin thinning, or excessive bruising);
  • proximal muscle weakness on exam; or
  • history of deep vein thrombosis/pulmonary embolism.
  • Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
  • Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
  • Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
  • Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
  • Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
  • Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
  • Known hypersensitivity to clofutriben or to any of the product

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dose 1

clofutriben .2 mg oral tablet daily

HSD-1 inhibitor

Andra namn:
  • SPI-62
  • ASP3662
Experimentell: Dose 2

clofutriben 2mg oral tablet daily

HSD-1 inhibitor

Andra namn:
  • SPI-62
  • ASP3662
Experimentell: Dose 3

clofutriben 6mg oral tablet daily

HSD-1 inhibitor

Andra namn:
  • SPI-62
  • ASP3662
Experimentell: Dose 4

clofutriben 12 mg oral tablet daily

HSD-1 inhibitor

Andra namn:
  • SPI-62
  • ASP3662
Placebo-jämförare: placebo

placebo control oral tablet daily

Placebo

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Tidsram: 8-10 hours after the dexamethasone 1 mg dose.

To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose.

8-10 hours after the dexamethasone 1 mg dose.
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Tidsram: 24 weeks.

To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Tidsram: 24 weeks

To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To evaluate the safety of clofutriben in participants with T2D and EC.
Tidsram: From enrollment until end of trial 9 month

Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose

From enrollment until end of trial 9 month

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 november 2025

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

30 juni 2028

Studieregistreringsdatum

Först inskickad

30 november 2025

Först inskickad som uppfyllde QC-kriterierna

18 december 2025

Första postat (Faktisk)

22 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera